Single-Agent Irinotecan as Second-Line Treatment for Advanced Gastric Cancer (original) (raw)
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Atsuo Takashima
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016
View PDFchevron_right
Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study
Vahur Valvere
Annals of Oncology, 2004
View PDFchevron_right
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer
Yuksel Kucukzeybek
Asian Pacific journal of cancer prevention : APJCP, 2012
View PDFchevron_right
Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma
G. Iconomou
Journal of Chemotherapy, 2007
View PDFchevron_right
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens
Erkan Arpaci
Journal of Chemotherapy, 2012
View PDFchevron_right
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
Michel Ducreux
British journal of cancer, 2003
View PDFchevron_right
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice
Manabu Muto
Gastric Cancer
View PDFchevron_right
A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer
Dong Shin
Cancer research and treatment : official journal of Korean Cancer Association, 2006
View PDFchevron_right
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
Dimitri Flieger
British Journal of Cancer, 2005
View PDFchevron_right
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Masaru Oba
Oncology letters, 2011
View PDFchevron_right
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
Jason Lee
Annals of Oncology, 2006
View PDFchevron_right
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
Kushal Gupta
South Asian Journal of Cancer, 2018
View PDFchevron_right
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum
Hiroshi Mihara
Anticancer research, 2013
View PDFchevron_right
Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study
Hiroshi Mihara
Gastroenterology research and practice, 2012
View PDFchevron_right
Weekly Irinotecan in Patients with Metastatic Gastric Cancer Failing Cisplatin-based Chemotherapy
Jong Chun
View PDFchevron_right
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
E. Goker
Annals of Oncology, 2008
View PDFchevron_right
A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma
Craig Earle
Digestive Diseases and Sciences, 2005
View PDFchevron_right
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)
David Cella
Anti-Cancer Drugs, 2011
View PDFchevron_right
A Phase II Study of Irinotecan With Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-Fluorouracil (Modified FOLFIRI) as First Line Therapy For Patients With Recurrent or Metastatic Gastric Cancer
Seong-Geun Kim
American Journal of Clinical Oncology, 2009
View PDFchevron_right
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy
Nikolaos Androulakis
Critical Reviews in Oncology/Hematology, 1999
View PDFchevron_right
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes
Dong Gyu Shin
Anti Cancer Drugs, 2005
View PDFchevron_right
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
Bruno Massidda
Cancer Chemotherapy and Pharmacology, 2009
View PDFchevron_right
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
Kenji Shimada
Cancer Chemotherapy and Pharmacology, 2001
View PDFchevron_right
Irinotecan in the Treatment of Advanced Colorectal Cancer in Patients Pretreated With Fluorouracil-Based Chemotherapy
Juan Carrasco
American Journal of Clinical Oncology, 2003
View PDFchevron_right
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study
Young Do
Journal of Korean medical science, 2005
View PDFchevron_right
A Multicenter Phase II Study of Irinotecan in Patients with Advanced Colorectal Cancer Previously Treated with 5-Fluorouracil
Pilar Gayoso-Diz
Clinical Colorectal Cancer, 2003
View PDFchevron_right
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
Gianluca Tomasello
Tumori
View PDFchevron_right